Eli Lilly and Company announced the successful completion of its acquisition of Dermira, Inc. Lilly completed the acquisition of Dermira through the merger of Bald Eagle Acquisition Corporation with and into Dermira, with Dermira surviving the merger as a wholly-owned subsidiary of Lilly.
As of the expiration of the tender offer, 40,926,025 shares of Dermira common stock were validly tendered and not properly withdrawn, representing approximately 74.8 percent of the shares of Dermira common stock outstanding, and have been accepted for payment under the terms of the tender offer. Following completion of the tender offer, Lilly completed the acquisition of Dermira through the previously-planned second-step merger.
“We are pleased to complete the acquisition of Dermira, and look forward to continuing their important work to develop new therapeutic options for patients with chronic skin conditions,” said Patrik Jonsson, Lilly senior vice president and president of Lilly Bio-Medicines.
The expected financial impact of Lilly’s acquisition of Dermira has been previously communicated and is reflected in Lilly’s current 2020 financial guidance, as announced on January 30, 2020.
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.